Eli Lilly Förvaltning
Förvaltning kriterier kontrolleras 2/4
Eli Lilly VD är Dave Ricks, utsedd i Jan 2017, har en mandatperiod på 9.67 år. totala årliga ersättningen är $ 36.70M, bestående av 4.6% lön 95.4% bonusar, inklusive företagsaktier och optioner. äger direkt 0.091% av företagets aktier, värda $ 915.81M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 7 år respektive 10.3 år.
Viktig information
Dave Ricks
Verkställande direktör
US$36.7m
Total ersättning
| VD-lön i procent | 4.63% |
| Anställning som VD | 9.7yrs |
| Ägande av VD | 0.09% |
| Ledningens genomsnittliga anställningstid | 7yrs |
| Styrelsens genomsnittliga mandatperiod | 10.3yrs |
Senaste uppdateringar av ledningen
Recent updates
Seeking Alpha • Sep 05
Eli Lilly Stock Is Not Done Growing Yet, But It's Due For Compression (Rating Downgrade)
Summary Eli Lilly remains attractive versus overextended semiconductor stocks, offering a compelling short-term entry point within healthcare's more favorable valuation landscape. LLY's forward P/E of 31.5 is high, but its PEG ratio of 1.49 suggests growth justifies the premium relative to sector peers. Healthcare, led by LLY, can benefit from rotation out of crowded tech but remains correlated to broader equity sentiment and vulnerable in a market-wide selloff. LLY's Q2 revenue surged 48% on Mounjaro and Zepbound, positioning it to potentially outperform semiconductors, though not immune to systemic risk. Read the full article on Seeking Alpha
Uppdatering av berättelse • Sep 05
LLY: Incretin Obesity Franchise And Pipeline Will Support Premium Positioning Beyond 2030
The analyst fair value estimate for Eli Lilly has been raised from $1,500 to $1,600 as analysts point to strong Q2 incretin volume, obesity drug demand, and upgraded multi-year guidance as key supports for higher long-term assumptions. Analyst Commentary Recent Street research on Eli Lilly points to a broadly constructive tone, with many bullish analysts lifting price targets after Q2 results and updated guidance.
Ny berättelse • Sep 03
Eli Lilly — Leader of the GLP-1 Revolution, but Priced for Success
Eli Lilly is the leader of the obesity/diabetes revolution (GLP-1 drugs like tirzepatide), addressing one of the largest addressable markets in medical history. It's my highest-quality healthcare growth bet.
Uppdatering av berättelse • Aug 22
LLY: Obesity Franchise Concentration And Pricing Pressure Will Constrain Future Upside
Analysts have lifted the Eli Lilly fair value estimate from $899.73 to $982.09. Higher price targets reflect confidence that strong incretin demand, obesity franchise momentum and updated long-term guidance support a slightly higher assumed future P/E and profit margin, even with a modestly higher discount rate and tempered revenue growth inputs.Analysartikel • Aug 08
Eli Lilly and Company Just Beat Revenue By 11%: Here's What Analysts Think Will Happen Next
Eli Lilly and Company ( NYSE:LLY ) just released its quarterly report and things are looking bullish. It was a positive...
Uppdatering av berättelse • Aug 08
LLY: GLP-1 Leadership And Retatrutide Progress Will Drive Balanced Outlook
Analysts have increased their fair value estimate for Eli Lilly stock from $1,270.37 to $1,297.31, reflecting higher Street price targets supported by strong Q2 incretin demand, GLP-1 franchise momentum, and updated long-term modeling around obesity and diabetes therapies. Analyst Commentary Recent Street research on Eli Lilly shows a clear focus on the company’s incretin and GLP-1 portfolio, with multiple firms adjusting price targets following Q2 results, obesity and diabetes trial updates, and refreshed long term models.Uppdatering av berättelse • Jul 25
LLY: GLP-1 Leadership And Retatrutide Data Will Shape Balanced Outlook
Eli Lilly's updated fair value estimate of $1,270.37, up from $1,243.43, reflects analysts' higher price targets that lean on expectations for stronger obesity and diabetes franchise contributions, incremental support from retatrutide data, and Q2 previews that factor in relatively higher revenue growth assumptions alongside slightly adjusted long term profit margins and future P/E multiples. Analyst Commentary Recent research on Eli Lilly points to a generally constructive stance from Wall Street, with multiple firms lifting price targets as they reassess the company's obesity and diabetes portfolio, retatrutide data, and Q2 earnings setup.Uppdatering av berättelse • Jul 10
LLY: GLP-1 Franchise And Retatrutide Data Will Support Balanced Future Outlook
Analysts have nudged their price targets on Eli Lilly higher, with fair value estimates moving from about $1,218.72 to roughly $1,243.43 as they point to resilient GLP-1 obesity and diabetes franchises, along with supportive recent data and previews around Zepbound, Mounjaro, Foundayo and retatrutide. Analyst Commentary Recent research updates on Eli Lilly show a cluster of higher price targets around the GLP-1 obesity and diabetes portfolio, with Zepbound, Mounjaro, Foundayo and retatrutide at the center of the discussion.Uppdatering av berättelse • Jun 24
LLY: Retatrutide Efficacy And GLP-1 Demand Will Support Balanced Outlook
Analysts have nudged up Eli Lilly's fair value estimate by about $4 to $1,218.72, reflecting modestly higher modeled revenue growth and a slightly richer future P/E multiple, supported by recent price target increases tied to retatrutide data and broader GLP-1 expectations. Analyst Commentary Recent commentary on Eli Lilly centers on how retatrutide data and GLP-1 demand expectations filter into valuation, growth assumptions, and execution risk.Uppdatering av berättelse • Jun 09
LLY: GLP-1 Leadership And Retatrutide Data Will Support Balanced Long-Term Outlook
Analysts have inched up their price targets on Eli Lilly, with several moving into the $1,250 to $1,350 range. They cite full Phase 3 retatrutide data that showed strong obesity and Type 2 diabetes outcomes, with what they view as manageable safety trade offs and a GLP-1 profile they say will be hard for rivals to match.Uppdatering av berättelse • May 26
LLY: GLP-1 Obesity Franchise Leadership Will Drive Long-Term Profitability
Analysts have nudged their price targets on Eli Lilly higher, with our fair value estimate moving by about $2 to $1,211 per share as they factor in expectations for stronger long-term profitability and GLP-1 leadership following positive retatrutide Phase 3 data, partly offset by more tempered revenue growth assumptions and a lower future P/E multiple. Analyst Commentary Recent research on Eli Lilly clusters around the same theme, retatrutide Phase 3 data supporting a premium valuation for the GLP-1 franchise, but with growing debate over how much future growth is already reflected in the stock.Uppdatering av berättelse • May 07
LLY: Obesity Pricing Pressure And Safety Headlines Will Shape Future Franchise Economics
Analysts have raised Eli Lilly's implied fair value from $883.99 to $899.73 after several firms increased their price targets by $1 to $50, citing confidence in the obesity and diabetes pipeline, Foundayo's regulatory progress, and clarifications around recent safety concerns. Analyst Commentary Recent research on Eli Lilly reflects a mix of enthusiasm around obesity and diabetes assets and a clearer, more cautious minority that is focused on how much optimism is already reflected in the stock.Uppdatering av berättelse • Apr 20
LLY: Obesity And Diabetes Platform Will Support Premium Positioning Beyond 2030
Analysts have slightly raised their average price targets on Eli Lilly in recent weeks, citing supportive trial updates in obesity and diabetes, favorable comparisons to competing GLP-1 therapies, and regulatory progress that they say supports high but unchanged fair value estimates of around $1,500. Analyst Commentary Recent Street research around Eli Lilly has been active, with a cluster of price target moves, rating changes, and product specific notes that give you a clearer sense of how professionals are framing the risk and reward.Uppdatering av berättelse • Apr 06
LLY: Oral GLP-1 Launch And Capacity Expansion Will Drive Future Obesity Upside
Analysts have nudged Eli Lilly's price target slightly higher by $1, reflecting updated views on obesity and diabetes franchises following recent Foundayo approval commentary and comparative GLP-1 data. Analyst Commentary Recent research on Eli Lilly clusters around obesity and diabetes, pricing dynamics in GLP-1 therapies, and the implications of new product approvals and trial readouts for long term growth and valuation.Ny berättelse • Mar 25
Eli Lilly: A Pipeline-Driven Growth Story Trading 30% Below What the Business Is Actually Worth
Eli Lilly already runs one of the fastest-growing drug businesses on earth, and its most powerful drug is not even approved yet. WHERE THE STOCK SITS TODAY The current price is around $907 (25/03/2026).Uppdatering av berättelse • Mar 23
LLY: Obesity And Diabetes Franchise Strength Will Support Premium Positioning
Analysts have raised their price target for Eli Lilly to $1,500, citing updated models that reflect slightly stronger assumed revenue growth, a marginally higher profit margin profile, and continued confidence in the obesity and diabetes franchises following recent trial data and supportive sell side research. Analyst Commentary Recent research highlights a split view on Eli Lilly, with some bullish analysts leaning into the obesity and diabetes opportunity set, while at least one more cautious voice questions how much growth is already reflected in the share price.Uppdatering av berättelse • Mar 09
LLY: Obesity Drug Leadership And Pipeline Catalysts Will Sustain Premium Positioning
The updated analyst price target for Eli Lilly has increased to $1,490.52 from $1,429.89. Analysts highlight the obesity and GLP-1 franchise, premium valuations tied to weight loss leadership, and potential upside from pipeline and acquisition catalysts as key factors supporting this change.Uppdatering av berättelse • Feb 23
LLY: GLP-1 Obesity Leadership Will Drive Future Cardiometabolic And M&A Upside
Eli Lilly's analyst price targets have shifted higher, with our fair value estimate moving from $1,093.22 to $1,211.21, as analysts point to sustained GLP-1 obesity leadership, premium valuation support, and an expanding cardiometabolic pipeline as key drivers of their updated views. Analyst Commentary Recent Street research on Eli Lilly clusters around a few clear themes, with bullish analysts focusing on obesity leadership, cardiometabolic breadth, and M&A, while more cautious voices watch valuation and execution risk around the pipeline.Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$27b |
| Mar 31 2026 | n/a | n/a | US$25b |
| Dec 31 2025 | US$37m | US$2m | US$21b |
| Sep 30 2025 | n/a | n/a | US$18b |
| Jun 30 2025 | n/a | n/a | US$14b |
| Mar 31 2025 | n/a | n/a | US$11b |
| Dec 31 2024 | US$29m | US$2m | US$11b |
| Sep 30 2024 | n/a | n/a | US$8b |
| Jun 30 2024 | n/a | n/a | US$7b |
| Mar 31 2024 | n/a | n/a | US$6b |
| Dec 31 2023 | US$27m | US$2m | US$5b |
| Sep 30 2023 | n/a | n/a | US$5b |
| Jun 30 2023 | n/a | n/a | US$6b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$21m | US$2m | US$6b |
| Sep 30 2022 | n/a | n/a | US$6b |
| Jun 30 2022 | n/a | n/a | US$6b |
| Mar 31 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$22m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$6b |
| Jun 30 2021 | n/a | n/a | US$6b |
| Mar 31 2021 | n/a | n/a | US$6b |
| Dec 31 2020 | US$24m | US$1m | US$6b |
| Sep 30 2020 | n/a | n/a | US$6b |
| Jun 30 2020 | n/a | n/a | US$6b |
| Mar 31 2020 | n/a | n/a | US$6b |
| Dec 31 2019 | US$21m | US$1m | US$5b |
Ersättning vs marknad: Dave s total kompensation ($USD 36.70M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 14.74M ).
Ersättning vs inkomst: Ersättningen för Dave har ökat med mer än 20 % det senaste året.
VD OCH KONCERNCHEF
Dave Ricks (58 yo)
9.7yrs
Anställning
US$36,698,337
Kompensation
Mr. David A. Ricks, also known as Dave, has been a Director of Adobe Inc. since April 12, 2018 and previously served as its Director since June 2017. He served as a Director of Elanco Animal Health Incorpo...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Chairman | 9.7yrs | US$36.70m | 0.091% $ 915.8m | |
| Executive VP & CFO | 2yrs | US$8.48m | 0.0018% $ 18.2m | |
| Chief Scientific & Product Officer and President of Lilly Research Laboratories | 8.3yrs | US$17.79m | 0.026% $ 264.7m | |
| Executive VP | 6.6yrs | US$9.85m | 0.0057% $ 56.8m | |
| Executive VP | no data | US$7.59m | 0.0041% $ 40.7m | |
| Senior VP of Finance & Chief Accounting Officer | 13.8yrs | inga uppgifter | 0.00037% $ 3.7m | |
| Executive VP and Chief Information & Digital Officer | 5.3yrs | US$5.10m | 0.0030% $ 29.6m | |
| Senior Vice President of Investor Relations | 7.8yrs | inga uppgifter | inga uppgifter | |
| Executive VP & Chief People Officer | 3.8yrs | inga uppgifter | 0.0016% $ 16.4m | |
| Executive VP and President of Lilly USA & Global Customer Capabilities | 5.9yrs | inga uppgifter | 0.0033% $ 33.4m | |
| Executive VP & President of Lilly International | 7yrs | US$3.92m | 0.0062% $ 61.6m | |
| Senior Vice President of Global Value & Access | 7.1yrs | inga uppgifter | inga uppgifter |
7.0yrs
Genomsnittlig anställningstid
53yo
Genomsnittlig ålder
Erfaren ledning: LLY s ledningsgrupp är erfaren och erfaren ( 7 års genomsnittlig anställning).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Chairman | 9.7yrs | US$36.70m | 0.091% $ 915.8m | |
| Independent Director | 5.7yrs | US$365.50k | 0.00033% $ 3.3m | |
| Chairman Emeritus | 17.7yrs | US$13.06m | inga uppgifter | |
| Independent Director | 20.8yrs | US$343.80k | 0.00019% $ 1.9m | |
| Independent Director | 17.4yrs | US$361.00k | 0.000090% $ 900.9k | |
| Independent Director | less than a year | US$7.68k | 0.00022% $ 2.2m | |
| Independent Director | 14.3yrs | US$392.00k | inga uppgifter | |
| Independent Director | 4.3yrs | US$339.00k | 0.000040% $ 400.4k | |
| Lead Independent Director | 10.6yrs | US$398.00k | 0.0019% $ 18.9m | |
| Independent Director | 14.8yrs | US$361.00k | inga uppgifter | |
| Independent Director | 9.9yrs | US$368.00k | 0.000020% $ 200.2k | |
| Independent Director | 5.6yrs | US$336.00k | inga uppgifter |
10.3yrs
Genomsnittlig anställningstid
64.5yo
Genomsnittlig ålder
Erfaren styrelse: LLY s styrelse är rutinerade och erfaren ( 10.3 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/09/11 22:02 |
| Aktiekurs vid dagens slut | 2026/09/11 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Eli Lilly and Company bevakas av 53 analytiker. 28 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Kerry Holford | Berenberg |